Q2Pharma

Q2Pharma is dedicated to developing innovative small-molecule drugs to combat multi-drug resistant (MDR) bacteria. Specializing in solutions that can be used with commonly used antibiotics or as stand-alone medications, Q2Pharma is at the forefront of addressing critical challenges in infectious disease. The company's lead compound, F19, has demonstrated significant potential in combating deadly MDR bacterial infections by inhibiting bacterial toxin release and potentiating antibiotic efficacy.

Located at 24 Ben-Gurion Blvd., Haifa, Israel 31000, IL, Q2Pharma focuses on stopping bacterial attacks and allowing the immune system to function more effectively. Recent experiments have highlighted F19’s potent effects on several of the most common and deadly MDR bacteria, positioning Q2Pharma as a key player in pre-clinical research, bacteriology, and pharmacology. Through rigorous clinical trials and a commitment to excellence, Q2Pharma aims to provide groundbreaking solutions to global health challenges.

Q2Pharma continues to advance its research and development efforts, striving to make a substantial impact on the treatment of infectious diseases. This dedication to innovation ensures that Q2Pharma remains a leader in the fight against multi-drug resistant bacteria. We invite the manager of Q2Pharma to create a customized and exclusive company showcase and product listing on our platform to further enhance their market presence.